Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 15/20 | 0.46 |
| ▸ | GUCY1B1 | Q02153 | 15/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CFD | P00746 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 2/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10071129 | 0.93 | GUCY1A1 (0.42) | GUCY1A1GUCY1B1CNR1CNR2CFD | |
| Hydrochloric Acid SCHEMBL20140172 | 0.92 | GUCY1A1 (0.41) | GUCY1A1GUCY1B1CNR1CNR2CFD | |
| SCHEMBL18999259 | 0.84 | CNR1 (0.38) | GUCY1A1GUCY1B1CNR1CNR2CFD | |
| SCHEMBL14777070 | 0.84 | CFD (0.38) | GUCY1A1GUCY1B1CNR1CNR2CFD | |
| Acetic Acid SCHEMBL15065428 | 0.83 | GUCY1A1 (0.43) | GUCY1A1GUCY1B1HTR3A | |
| SCHEMBL13734557 | 0.81 | GUCY1A1 (0.39) | GUCY1A1GUCY1B1CNR1CNR2CFD | |
| SCHEMBL13733845 | 0.81 | GUCY1A1 (0.43) | GUCY1A1GUCY1B1CNR1CNR2CFD | |
| SCHEMBL20161332 | 0.80 | GUCY1A1 (0.39) | GUCY1A1GUCY1B1CNR1CNR2CFD | |
| SCHEMBL10063587 | 0.79 | CFD (0.43) | CNR1CNR2CFD | |
| Acetic Acid SCHEMBL16245022 | 0.76 | ADORA3 (0.45) | GUCY1A1GUCY1B1CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9505786-B2 | Substituted annulated triazines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-29 | — | — | US | disclosed |
| US-20150274754-A1 | SUBSTITUTED ANNULATED TRIAZINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-01 | — | — | US | disclosed |
| US-9090610-B2 | Fluoroalkyl-substituted pyrazolopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-8765769-B2 | Ring-fused 4-aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-01 | — | — | US | disclosed |
| US-20140100229-A1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-10 | — | — | US | disclosed |
| US-20130172372-A1 | RING-FUSED 4-AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172372-A1 | RING-FUSED 4-AMINOPYRIMIDINES AND USE THEREOF AS STIMULATORS OF SOLUABLE GUANYLATE CYCLASES | GUCY1B1, GUCY1A2, GUCY1B2 | GUCY1A1 4/4885GUCY1B1 1/4885CNR1 2211/4885 |
| US-20150274754-A1 | SUBSTITUTED ANNULATED TRIAZINES AND USE THEREOF | TPMT, GOT2, TYMP | GUCY1A1 3397/4885GUCY1B1 2530/4885CNR1 3056/4885 |
| US-20140100229-A1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | PON1, QDPR, FABP3 | GUCY1A1 2148/4885GUCY1B1 1166/4885CNR1 2183/4885 |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | TYMP, DPYD, TYMS | GUCY1A1 3578/4885GUCY1B1 2644/4885CNR1 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.